Literature DB >> 10629105

Differentiation and malignant transformation: two roads diverged in a wood.

R Baserga1, A Morrione.   

Abstract

Growth factors and their receptors are known to send at times contradictory signals, such as proliferation or differentiation. Recent developments in our knowledge of growth factor receptors and their signaling pathways have clarified the basis for this puzzling behavior. Separate domains of a receptor and/or the availability of specific substrates determine the fate of a cell stimulated by the same growth factor. In some models, the difference between malignant transformation and differentiation (leading to cell death) may depend on the presence or absence of a single agonist or antagonist molecule. The type 1 insulin-like growth factor receptor will serve as the paradigm for this review. J. Cell. Biochem. Suppls. 32/33:68-75, 1999. Copyright 1999 Wiley-Liss, Inc.

Mesh:

Substances:

Year:  1999        PMID: 10629105     DOI: 10.1002/(sici)1097-4644(1999)75:32+<68::aid-jcb9>3.0.co;2-0

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  Regulation of Id gene expression by type I insulin-like growth factor: roles of Stat3 and the tyrosine 950 residue of the receptor.

Authors:  M Prisco; F Peruzzi; B Belletti; R Baserga
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

2.  Regulation of insulin-like growth factor type I (IGF-I) receptor kinase activity by protein tyrosine phosphatase 1B (PTP-1B) and enhanced IGF-I-mediated suppression of apoptosis and motility in PTP-1B-deficient fibroblasts.

Authors:  Deirdre A Buckley; Alan Cheng; Patrick A Kiely; Michel L Tremblay; Rosemary O'Connor
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin.

Authors:  David Metalli; Francesca Lovat; Farida Tripodi; Marco Genua; Shi-Qiong Xu; Michela Spinelli; Lilia Alberghina; Marco Vanoni; Raffaele Baffa; Leonard G Gomella; Renato V Iozzo; Andrea Morrione
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

Review 4.  IGF-I receptor signalling in transformation and differentiation.

Authors:  B Valentinis; R Baserga
Journal:  Mol Pathol       Date:  2001-06

5.  Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling.

Authors:  Renato V Iozzo; Simone Buraschi; Marco Genua; Shi-Qiong Xu; Charalambos C Solomides; Stephen C Peiper; Leonard G Gomella; Rick C Owens; Andrea Morrione
Journal:  J Biol Chem       Date:  2011-08-12       Impact factor: 5.157

6.  Characterization of DNA variants in the human kinome in breast cancer.

Authors:  Divyansh Agarwal; Yuan Qi; Tingting Jiang; Xiuping Liu; Weiwei Shi; Vikram B Wali; Benjamin Turk; Jeffrey S Ross; W Fraser Symmans; Lajos Pusztai; Christos Hatzis
Journal:  Sci Rep       Date:  2015-09-30       Impact factor: 4.379

Review 7.  Ligand-mediated endocytosis and trafficking of the insulin-like growth factor receptor I and insulin receptor modulate receptor function.

Authors:  Alaide Morcavallo; Manuela Stefanello; Renato V Iozzo; Antonino Belfiore; Andrea Morrione
Journal:  Front Endocrinol (Lausanne)       Date:  2014-12-17       Impact factor: 5.555

8.  Long noncoding RNA CCAT2 reduces chemosensitivity to 5-fluorouracil in breast cancer cells by activating the mTOR axis.

Authors:  Daoping Zhou; Juan Gu; Yueping Wang; Bing Luo; Mei Feng; Xuedong Wang
Journal:  J Cell Mol Med       Date:  2022-02-15       Impact factor: 5.310

9.  Proline-rich tyrosine kinase 2 (Pyk2) regulates IGF-I-induced cell motility and invasion of urothelial carcinoma cells.

Authors:  Marco Genua; Shi-Qiong Xu; Simone Buraschi; Stephen C Peiper; Leonard G Gomella; Antonino Belfiore; Renato V Iozzo; Andrea Morrione
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.